Lenz Therapeutics' eye disease drugs meet main goal of late-stage study
==========

Lenz Therapeutics announced that its experimental drugs to treat loss of near vision met the main goal of a late-stage study. The lead product candidate, LNZ100, showed statistically significant improvement in patients' ability to see details at a distance of 20 feet at three hours post-treatment. The other drug, LNZ101, also showed similar results but did not show superiority to LNZ100. Lenz plans to submit a marketing application for LNZ100 in the United States in mid-2024.

#LenzTherapeutics #EyeDiseaseDrugs #LatestageStudy #Lnz100 #Lnz101 #VisionLoss #Treatment #MarketingApplication

https://www.investing.com/news/stock-market-news/lenz-therapeutics-eye-disease-drugs-meet-main-goal-of-latestage-study-3363544